
CureVac B.V (CVAC) Stock Forecast & Price Target
CureVac B.V (CVAC) Analyst Ratings
Bulls say
CureVac NV is positioned favorably within the competitive mRNA market, which benefits from high demand stemming from COVID-19 vaccines and the anticipated broader applications of mRNA technology. The company's collaboration with GSK on developing second-generation vaccines for seasonal influenza and COVID-19, as well as an avian influenza vaccine, underscores its innovative approach and strategic partnerships in the vaccine space. Furthermore, CureVac's ongoing development of a diverse pipeline, including mRNA vaccines for oncology and therapies targeting various diseases, highlights its commitment to advancing cutting-edge solutions that could enhance patient outcomes.
Bears say
CureVac NV is expected to continue incurring significant net losses until product approval and commercialization, raising concerns about its financial sustainability in the interim. The company faces substantial competitive risks, as it may struggle to effectively compete against both established players and other in-development candidates in the mRNA vaccine market. Additionally, potential legal and intellectual property challenges could adversely affect CureVac's market position and overall sales, further contributing to the negative outlook on its stock.
This aggregate rating is based on analysts' research of CureVac B.V and is not a guaranteed prediction by Public.com or investment advice.
CureVac B.V (CVAC) Analyst Forecast & Price Prediction
Start investing in CureVac B.V (CVAC)
Order type
Buy in
Order amount
Est. shares
0 shares